Key result
Adjunctive HBOT for ACS is linked to ~42% lower mortality in small, potentially biased trials.
Why the study?
The effects of adjunctive hyperbaric oxygen therapy in the treatment of acute coronary syndrome remain uncertain due to small trials and methodological shortcomings.
Does adjunctive hyperbaric oxygen therapy reduce the risk of death and major adverse cardiac events in patients with acute coronary syndrome?
Comparison
Regimens including adjunctive HBOT versus regimens excluding HBOT
Design
Systematic review of randomized trials with intention to treat analysis
Authors
Loading...
Low-quality evidence precludes routine adjunctive hyperbaric oxygen use in acute coronary syndrome; larger rigorous trials needed to confirm mortality benefit.
Systematic Review (n=665)
Does adjunctive hyperbaric oxygen therapy reduce the risk of death and major adverse cardiac events in patients with acute coronary syndrome?
Relative Risk: 0.58 (95% CI 0.36–0.92)
Adjunctive hyperbaric oxygen therapy may reduce the risk of death in acute coronary syndrome, but the evidence is of low quality and routine application cannot be justified without further rigorous trials.
Bennett et al. (2015) conducted a systematic review in Acute coronary syndrome (n=665). Hyperbaric oxygen therapy (HBOT) vs. Standard treatment excluding HBOT was evaluated on Death (RR 0.58, 95% CI 0.36 to 0.92). Adjunctive hyperbaric oxygen therapy for acute coronary syndrome was associated with a reduced risk of death (RR 0.58; 95% CI 0.36-0.92), though evidence is limited by small, potentially biased trials.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: